Secondary Logo

Journal Logo

Skin and subcutaneous infections in south-east Asia

Nor, Norazirah Md.; Baseri, Mazlin M.

Current Opinion in Infectious Diseases: April 2015 - Volume 28 - Issue 2 - p 133–138
doi: 10.1097/QCO.0000000000000150
SKIN AND SOFT TISSUE INFECTIONS: Edited by Matthew S. Dryden
Free

Purpose of review We reviewed current literature on four different skin and subcutaneous infections which are often touted as ‘emerging diseases’ of south-east Asia, namely melioidosis, penicilliosis, sporotrichosis and Mycobacterium marinum infection. Lack of consensus treatment guidelines, high treatment costs and limited investigative capability in certain endemic areas are among the challenges faced by managing physicians. With the increase in borderless travelling, it is hoped that this review will facilitate better understanding and heighten the clinical suspicion of such infections for clinicians in other parts of the world.

Recent findings An increasing number of cases of melioidosis and penicilliosis have been reported within and outside its endemic areas, but epidemiological data on sporotrichosis and M. marinum infections are still sparse. The clinical features of these infections remain historically unchanged and more disseminated infections are seen particularly amongst immunocompromised patients. Although tissue culture is still the gold standard, PCR provides more rapid and accurate diagnosis. Advances in therapeutics have improved outcome in certain diseases.

Summary The described spectrum of cutaneous infection in south-east Asia can be imported to other areas due to increases in worldwide travel. Clinicians from other parts of the world should be aware of the common presentations of these diseases.

Dermatology Unit, Medical Department, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latiff, Kuala Lumpur, Malaysia

Correspondence to Norazirah Md. Nor, MBBCh (Cardiff), MRCP (UK), AdvM Derm (UKM), Dermatologist and Lecturer, Dermatology Unit, Medical Department, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latiff, 56000 Kuala Lumpur, Malaysia. Tel: +6-03-91456505; e-mail: norazirah78@gmail.com

Back to Top | Article Outline

INTRODUCTION

South-east Asia is well known for its tropical weather, with high humidity being its most striking feature. Several cutaneous infections seen in this region involve organisms that mainly originate from soil and natural water sources. Here, we review the pathogenesis, clinical features, investigations and treatment of skin and subcutaneous infections of melioidosis, penicilliosis, sporotrichosis and Mycobacterium marinum that are endemic in south-east Asia.

Box 1

Box 1

Back to Top | Article Outline

MELIOIDOSIS

Melioidosis is a disease caused by Burkholderia pseudomallei, a Gram-negative bacillus which is a natural inhabitant of soil and environmental water. It is endemic to south-east Asia and northern Australia [1] and imported cases occur in travellers to these areas.

In Thailand, B. pseudomallei accounts for up to approximately 20% of community-acquired bacteraemias [2]. The disease has a male preponderance, especially in those who have occupational or recreational contact with soil and water. Diabetes mellitus, alcoholism, renal disease, chronic lung disease, thalassaemia and steroid therapy increase the risk of acquiring the infection [3,4] but it is also known to occur in otherwise healthy patients. For cutaneous melioidosis, however, these traditional risk factors appear to be less important.

Infection occurs by percutaneous inoculation, aerosol inhalation or ingestion of contaminated food or water [5]. The incubation period is highly variable and it ranges between 1 and 21 days [6] to the longest duration reported being 62 years [7]. Mortality is much higher in septicaemic (30–70%) than in nonsepticaemic patients (5–20%) [8]. Clinical features are protean and vary from indolent, chronic infection to an acute fulminant septicaemia. The skin is the third commonest organ to be involved after the lungs and genitourinary tract in Malaysia and Thailand [9]. Skin and soft tissue involvement accounts for 13–24% of clinical presentation of melioidosis in a case series from Australia [10].

Cutaneous melioidosis may present as primary or secondary lesions. Primary lesions present as chronic ulcers, abscesses, cellulitis and necrotizing fasciitis [11,12]. Patients with primary cutaneous disease tend to be younger, and have less predisposing factors for melioidosis, milder disease and better outcome compared to melioidosis of other organs [5]. Studies have also shown that children with melioidosis in south-east Asia are more likely to have localized disease [13,14]. Secondary cutaneous lesions may present as pustules from haematogenous spread or as extensions from an underlying infection such as osteomyelitis or lymphangitis [15]. Other rarer presentations include scrotal abscess, Fournier's gangrene, parotitis and prostatitis [16–19].

Positive culture of B. pseudomallei remains the gold standard for the diagnosis of melioidosis. Isolation of the organism from a patient with suspected melioidosis should be viewed as highly likely to represent infection [20] but the special selective media may require up to 5 days of incubation for a positive result [21].

Patients with cutaneous melioidosis warrant thorough investigation to look for disseminated disease. Blood and other cultures, chest radiograph and abdominopelvic imaging should be performed. Direct PCR assay provides a more rapid and specific test result and is a promising tool for clinical use. This assay, however, is less sensitive to culture especially when performed on blood [22,23]. The usefulness of a serological test to detect B. pseudomallei – specific antibodies such as the indirect haemagglutination assay and enzyme-linked immunosorbent assays are limited in endemic areas because the background positivity may reach up to 50% [24].

The recommended treatment regimen is prolonged and consists of an intensive phase followed by a maintenance or oral eradication phase. During the intensive phase, intravenous ceftazidime or carbapenem is administered for 10–14 days. The oral eradication therapy is given for 3–6 months. Recently a study showed noninferiority and better tolerability of trimethoprim–sulphamethoxazole (TMP-SMX) alone compared to TMP-SMX along with doxycycline for 20 weeks [25▪▪]. Optimal duration of treatment, however, remains undetermined and it varies in different localities. There have been reports of cutaneous melioidosis treated with solely oral antibiotics with or without surgical drainage with good outcomes [7,14] but there are no clinical trials comparing the outcome of the two treatment approaches in localized cutaneous disease.

The search for an ideal vaccine is still ongoing and vaccine candidates include live attenuated, whole cell killed, subunit, plasmid DNA and dendritic cell vaccines. A cost-effectiveness analysis in Thailand has shown that a vaccine may be cost-effective especially when applied to high-risk groups [26]. A live attenuated vaccine was found to be the most effective immunogen in mice but its potential to cause life-threatening disease that is difficult to treat and the possibility that it may become a latent infection render it unsuitable for use in humans [27].

Back to Top | Article Outline

PENICILLIOSIS

Penicilliosis is caused by a dimorphic fungus Penicillium marneffei, which is now renamed Talaromyces marneffei. It is the third most common opportunistic infection in HIV patients in south-east Asia [28] and may occur in HIV patients travelling to endemic areas [29]. Its exact incidence remains unknown but it mirrors the changes in the trend of HIV pandemicity in this region.

Penicilliosis is endemic in countries such as Malaysia, Thailand, Vietnam, Cambodia, southern China and India [30] most likely due to the humidity, which is an important factor in P. marneffei infection [31▪]. Occupational and other exposures to soil, particularly in the rainy seasons, have been identified as a significant risk factor for disseminated penicilliosis [32] and this suggests the soil as the main reservoir for the organism. Isolation of P. marneffei in organs of bamboo rats which rarely come in contact with humans also supported that both humans and rats may have acquired the infection from a common environmental source such as the soil [33,34].

Penicilliosis transmission is via an airborne route. Inhaled P. marneffei conidia are engulfed by the macrophages and processed in the reticulo-endothelial system [35]. The organisms then remain dormant and proliferate upon deterioration of the immune system of the host. It is considered as one of the AIDS-defining illnesses in south-east Asia as it affects patients with CD4 (cluster of differentiation 4) count lower than 200 cell/μl. Infection in HIV negative patient is rare but has been reported [36].

The spectrum of infection ranges from isolated cutaneous to disseminated infection. Cutaneous penicilliosis presents as multiple dome-shaped skin-coloured, umbilicated papules and nodules with or without central necrosis on the face and trunk. Other associated symptoms and signs such as fever, malaise, weight loss, anaemia, lymphadenopathy and hepatosplenomegaly are present in disseminated penicilliosis [37]. In more than 70% of HIV patients, the presence of cutaneous penicilliosis suggests disseminated infection [38,39] and this warrants further investigation to determine the involvement of other organs. HIV-negative children with penicilliosis need to be screened for primary immunodeficiency diseases, which may predispose them to the infection [40].

Isolation of P. marneffei from tissue culture is the gold standard for diagnosis [30]. Preliminary diagnosis can be made in the presence of classic cutaneous lesions and visualization of the organism in the skin biopsy using Gomori-methenamine silver or Wright's stain. Histologically, P. marneffei is an oval-shaped yeast-like organism measuring 3–8 μm with central septation [41]. In cases of disseminated penicilliosis, fungal cultures from bone marrow aspiration provide 100% yield, followed by skin biopsy (90%) and blood cultures (76%) [42]. PCR-based detection is the investigation of choice as it provides highly sensitive and rapid diagnosis [43].

Intravenous amphotericin B at 0.6 mg/kg/day for 2 weeks followed by 10 weeks of oral itraconazole 400 mg daily is the recommended treatment in severe or disseminated infection. Success in treating severe infections using itraconazole or fluconazole alone has been reported [44▪] but fluconazole is the least effective azole against P. marnaffei in vitro[45]. Voriconazole has been shown to be effective in several studies and is now a recommended alternative treatment for both severe and mild disease forms in the United States. In HIV patients, secondary prophylaxis with itraconazole 200 mg daily is recommended to prevent relapse or reinfection after a successful treatment [46]. This can be safely discontinued once the patient has sustained CD4 count of more than 100 cells/μl [47]. Primary prevention for penicilliosis is recommended in immunocompromised patients. It was demonstrated that fluconazole 400 mg weekly is as efficacious as itraconazole 200 mg daily in preventing infection [48]. If left untreated, penicilliosis will be fatal. Early diagnosis and treatment improves a patient's outcome.

Back to Top | Article Outline

SPOROTRICHOSIS

Sporotrichosis is a subacute or chronic granulomatous subcutaneous mycosis caused by traumatic inoculation of Sporothrix schenckii, a saprophytic dimorphic fungus which is commonly found in soil and plant matter. Zoonotic transmission from cats and other animals has also been described [49]. The clinical presentation is divided into four types: lymphocutaneous, fixed cutaneous, disseminated and extracutaneous. The lymphocutaneous type is the commonest variant followed by fixed cutaneous in this region [50].

Lesions most commonly affect the extremities in adolescents and adults, but in infants and children, the face is the most common site [51,52]. Most cases are limited to skin and soft tissues but disseminated disease and extracutaneous involvement are rare and occur in immunocompromised individuals [53].

Disseminated sporotrichosis has also been reported to occur and worsen after initiation of HAART in two patients with AIDS as part of immune reconstitution inflammatory syndrome [54]. Sporotrichosis outbreaks have been reported from various countries such as Western Australia (from contaminated hay) [55] and Brazil (from infected cats) [56].

Diagnosis is often made based on history, physical signs, histopathological examination and positive cultures. Identification using PCR can also be performed on tissue biopsy for rapid diagnosis [57].

Management of cutaneous sporotrichosis depends on its variant. For fixed and lymphocutaneous types, oral itraconazole for 3–6 months, or terbinafine or a saturated solution of potassium iodide (SSKI) is recommended. For disseminated or extracutaneous disease (pulmonary, meningeal, osteoarticular), intravenous amphotericin B is advocated with itraconazole as the ‘step-down’ treatment to complete the duration of at least 12 months [54].

Azoles are currently the preferred choice of treatment but due to the high cost, several studies were carried out to determine the efficacy and safety of alternative regimens. Bonifaz et al.[58] showed that pulse itraconazole was effective in treating cutaneous sporotrichosis. In a comparative study, Song et al.[59] demonstrated similar efficacy and safety of itraconazole pulse regimen (200 mg bd for 1 week with a 3 week break) to the continuous (100 mg bd) regimen. Terbinafine 250 mg daily is equally efficacious as itraconazole 100 mg daily for cutaneous sporotrichosis [60] and has also been shown to be a well tolerated alternative in cases when itraconazole is contraindicated or resulted in significant drug interactions [61]. Ketoconazole is not recommended because of its inferior efficacy and significant adverse effects [54]. SSKI is the oldest drug used for sporotrichosis and remains the mainstay of treatment in certain endemic areas. It is cheap and effective and therefore ideal for resource-limited settings [62]. It is initiated at a dosage of five drops three times daily, increasing to 40–50 drops three times daily as tolerated [54].

Back to Top | Article Outline

MYCOBACTERIUM MARINUM

M. marinum infection is rare but it is the most common nontuberculous mycobacterial infection in humans. The incidence in south-east Asia is not known due to the difficulty in obtaining positive cultures. This ubiquitous waterborne organism occupies both salt and fresh water. Its infection should be suspected in patients with a history of domestic, occupational and recreational exposure to unchlorinated water. Direct cutaneous inoculation of the organism through abrasions would result in granulomatous skin lesions within weeks or months [63].

The organism grows optimally at 25–32 °C, which explains its predilection for cooler parts of the body, that is the extremities. A nodule or pustule develops after an incubation period of 2–3 weeks, which ruptures to form an ulcer or suppurative abscess. Untreated, the lesions may heal spontaneously with scarring or progress to form multiple sporotrichoid lesions [64]. Its clinical features have been classified into four categories: single/limited (<3 lesions), numerous lesions in sporotrichoid distribution (>3 lesions), deep infection with or without skin involvement (such as arthritis, tenosynovitis and/or osteomyelitis) and disseminated infection (lungs and other organs) [65]. Disseminated disease is rare and has only been documented in immunocompromised patients [66] including those on tumour necrosis factor (TNF) inhibitors [67]. Diagnosis is often delayed due to its rarity, prior treatment with corticosteroids and lack of history of exposure to aquatic environment.

Skin biopsies should be sent for histopathological examination and culture, although poor yield (<15%) of positive isolates has been reported [68]. To improve the yield, clinicians should alert the microbiology laboratory regarding the possibility of this infection so that appropriate incubation and culture measures can be taken [69]. Antibiogram results, if available, will be invaluable to guide management. Species identification of mycobacterium can be performed using PCR analysis [70] but this investigation may not be available in many centres.

There are no randomized-controlled trials to establish the treatment of choice for cutaneous infection. Choice of antibiotics and duration of treatment are often based on personal preference of the managing physician, local or international society guidelines. Empirical treatment has to be given in cases wherein the culture is negative. Monotherapies using minocycline, doxycycline or TMP-SMX are well tolerated and effective [71]. Optimal duration of treatment varies, ranging from 1 to 25 months (median 3.5 months) [72].

A review by Rallis et al.[72] concluded that monotherapy is recommended for limited superficial infection using tetracyclines (minocycline 100 mg bd or doxycycline 100 mg bd), TMP-SMX 800 mg bd or clarithromycin 500 mg bd. Other effective alternatives include ciprofloxacin 500 mg bd and azithromycin 500 mg od. A combination of two drugs may be required in the presence of drug resistance. In immunocompromised patients or a patient who presents with nodules, abscess and/or sporotrichoid lesions, a combination of rifampicin 600 mg od and ethambutol 15–25 mg/kg/day is the most recommended regimen [73]. Clinicians should be aware that most M. marinum are intrinsically resistant to isoniazid, streptomycin and pyrazinamide [73,74].

Surgical excision of a localized disease is an option in certain cases. Other effective adjunctive treatment includes local heat therapy, cryotherapy, photodynamic therapy and electrodessication [75]. Surgical debridement may be indicated in cases wherein deeper structures are involved. In disseminated disease, combination therapy of three drugs may be required [76].

Preventive measures to reduce M. marinum infections include advising ‘fish fanciers’ to wear gloves when handling fish tank or tropical fish and for immunosuppressed individuals to avoid direct contact with aquarium or aquatic animals. Free chlorine concentrations in swimming pool and tub water should be maintained within the ranges recommended by the Centers for Disease Control and Prevention [63]. Common disinfectants such as ethyl alcohol, benzyl-4-chlorophenol and sodium chlorite have been shown to be the most effective to reduce or eliminate the organism from an aquarium or aquaculture facility [77]. There are no vaccines available but research on the use of M. marinum as potential immunotherapy for tuberculosis is under way [78].

Back to Top | Article Outline

CONCLUSION

Melioidosis, penicilliosis, sporotrichosis and M. marinum are endemic in south-east Asia. A high index of suspicion is required in diagnosing these infections in individuals who have visited the endemic area when they present with typical cutaneous lesions. Tissue biopsy for histology and culture is vital and PCR may facilitate instant and accurate diagnosis. Treatment for melioidosis and M. marinum requires prolonged duration of combination therapy. Appropriate antifungal treatment improves outcome in penicilliosis and sporotrichosis.

Back to Top | Article Outline

Acknowledgements

The authors thank Universiti Kebangsaan Malaysia for the support in preparation of this manuscript.

Back to Top | Article Outline

Financial support and sponsorship

None.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest
Back to Top | Article Outline

REFERENCES

1. White NJ. Melioidosis. Lancet 2003; 361:1715–1722.
2. Chaowagul W, White NJ, Dance DA, et al. Melioidosis: a major cause of community-acquired septicaemia in northeastern Thailand. J Infect Dis 1989; 159:890–899.
3. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, et al. Increasing incidence of human melioidosis in northeast Thailand. Am J Trop Med Hyg 2010; 82:1113–1117.
4. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010; 4:1–11.
5. Gibney KB, Cheng AC, Currie BJ. Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature. Clin Infect Dis 2008; 47:603–609.
6. Currie BJ, Fisher DA, Howard DM, et al. The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop 2000; 74:121–127.
7. Ngauy V, Lemeshev Y, Sadkowski L, et al. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 2005; 43:970–972.
8. Puthucheary SD, Vadivelu J. Human melioidosis. Med J Malaysia 2009; 64:266–274.
9. Puthucheary SD, Parasakthi N, Lee MK. Septicaemic melioidosis: a review of 50 cases from Malaysia. Trans R Soc Trop Med Hyg 1992; 86:683–685.
10. Cheng A, Currie BJ. Melioidosis: epidemiology, pathophysiology and management. Clin Microbiol Rev 2005; 18:383–416.
11. Wang YS, Wong CH, Kurup A. Cutaneous melioidosis and necrotizing fasciitis caused by Burkholderia pseudomallei. Emerg Infect Dis 2003; 9:1484–1485.
12. Lim WK, Gurdeep GS, Norain K. Melioidosis of the head and neck. Med J Malaysia 2001; 56:471–477.
13. How HS, Ng KH, Yeo HB, et al. Pediatric melioidosis in Pahang, Malaysia. J Microbiol Immunol Infect 2005; 38:314–319.
14. Sam IC, Puthucheary SD. Melioidosis in children from Kuala Lumpur, Malaysia. Ann Trop Paediatr 2006; 26:219–224.
15. Deris ZZ, Hasan H, Mohd Noor SS. Clinical characteristics and outcomes of bacteraemicmelioidosis in a teaching hospital in a north-eastern state of Malaysia: a five-year review. J Infect Dev Ctries 2010; 4:430–435.
16. Dance DA. Melioidosis: the tip of the iceberg? Clin Microbiol Rev 1991; 4:52–60.
17. Hsueh PR, Teng LJ, Lee LN, et al. Melioidosis: an emerging infection of Taiwan? Emerg Infect Dis 2001; 7:428–433.
18. Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 2000; 31:981–986.
19. Tran D, Tan HH. Cutaneous melioidosis. Clin Exp Dermatol 2002; 27:280–282.
20. Limmatuhurotsakul D, Peacock SJ. Melioidosis: a clinical overview. Br Med Bull 2011; 99:125–139.
21. Supaprom C, Wang D, Leelayuwat C, et al. Development of real-time PCR assays and evaluation of their potential use for rapid detection of Burkholderia pseudomallei in clinical blood specimens. J Clin Microbiol 2007; 45:2894–2901.
22. Richardson LJ, Kaestli M, Mayo M, et al. Towards a rapid molecular diagnostic for melioidosis: comparison of DNA extraction methods from clinical specimens. J Microbiol Methods 2013; 88:179–181.
23. Chantratita N, Wuthiekanun V, Limmathurotsakul D, et al. Prospective clinical evaluation of the accuracy of 16S rRNA real-time PCR assay for the diagnosis of melioidosis. Am J Trop Med Hyg 2007; 77:814–817.
24. Wuthiekanun V, Chierakul W, Langa S, et al. Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. Am J Trop Med Hyg 2006; 74:1074–1075.
25▪▪. Chetchotisakd P, Chierakul W, Chaowagul W, et al. Trimethoprim–sulfamethoxazole versus trimethoprim–sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double–blind, noninferiority, randomised controlled trial. Lancet 2014; 383:807–815.

This multicentre RCT demonstrated noninferiority of TMP-SMX plus placebo compared to TMP-SMX plus doxycycline for 20 weeks as oral eradication therapy (target HR 1.7) and TMP-SMX plus placebo was associated with less adverse drug reactions.

26. Peacock SJ, Limmathurotsakul D, Lubell Y, et al. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis 2012; 6:1–8.
27. Sarkar-Tyson M, Titball RW. Progress toward development of vaccines against melioidosis: a review. Clin Therapeut 2010; 32:1437–1445.
28. Supparatpinyo K, Khamwan C, Baosoung V, et al. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110–113.
29. Jung JY, Jo GH, Kim HS, et al. Disseminated penicilliosis in a Korean human immunodeficiency virus infected patient from Laos. J Korean Med Sci 2012; 27:697–700.
30. Wong SYN, Wong KF. Penicillium marneffei Infection in AIDS. Pathol Res Int 2011; 1–10.Article ID 764293:.
31▪. Bulterys PL, Le T, Quang VM, et al. Environmental predictors and incubation period of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Vietnam. Environmental predictors of penicilliosis. Clin Infect Dis 2013; 56:1–7.

This study significantly demonstrated that environmental humidity is an important factor and also a predictor of an increase in hospital admissions due to penicilliosis in Vietnam. This most likely explained why penicilliosis is prevalent in south-east Asia.

32. Chariyalertsak S, Sirisanthana T, Supparatpinyo K, et al. Case–control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand. Clin Infect Dis 1997; 24:1080–1086.
33. Ajello L, Padhye AA, Sookroongreung S, et al. Occurrence of Penicillium marneffei infections among wild bamboo rats in Thailand. Mycopathologia 1995; 131:1–8.
34. Chariyalertsak S, Vanittanakom P, Nelson KE, et al. Rhizomys sumatrensis and Cannomys badius, new natural animal hosts of Penicillium marneffei. J Med Vet Mycol 1996; 34:105–110.
35. Han J, Lun WH, Meng ZH, et al. Mucocutaneous manifestations of HIV-infected patients in the era of HAART in Guangxi Zhuang Autonomous Region, China. J Eur Acad Dermatol Venereol 2013; 27:376–382.
36. Liu GN, Huang JS, Zhong XN, et al. Penicillium marneffei infection within an osteolytic lesion in an HIV-negative patient. Int J Infect Dis 2014; 23:1–3.
37. Zhou F, Bi X, Zou X, et al. Retrospective analysis of 15 cases of Penicilliosis marneffei in a southern China hospital. Mycopathologia 2014; 177:271–279.
38. Rangwala F, Putcharoen O, Bowanwatanuwong C, et al. Histoplasmosis and penicilliosis in HIV infected Thai patients: a retrospective review. Southeast Asian J Trop Med Public Health 2012; 43:436–441.
39. Larsson M, Nguyen LHT, Wertheim HFL, et al. Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam. AIDS Res Ther 2012; 9:1–5.
40. Lee PPW, Chan KW, Lee TL, et al. Penicilliosis in children without HIV infection—are they immunodeficient? Clin Infect Dis 2012; 54:e8-e19.
41. High WA, Bravo FG. Emerging diseases in tropical dermatology. Adv Dermatol 2007; 23:335–350.
42. Nor-Hayati S, Sahlawati M, Suresh-Kumar C, Christopher Lee KC. A retrospective review on successful management of Penicillium Marneffei infections in patients with advanced HIV in Hospital Sungai Buloh. Med J Malaysia 2012; 67:66–70.
43. Sun J, Najafzadeh MJ, Zhang J, et al. Molecular identification of Penicillium marneffei using rolling circle amplification. Mycoses 2011; 54:e751–e759.
44▪. Hu Y, Zhang J, Li X, et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia 2013; 175:57–67.

This article reported the largest collection of penicilliosis cases involving 688 patients in China covering clinical spectrum, investigations and outcome of treatment of penicilliosis in immunocompromised patients as well as patients without any documented illness.

45. Liu D, Liang L, Chen J. In vitro antifungal drug susceptibilities of Penicillium marneffei from China. J Infect Chemother 2013; 19:776–778.
46. Yanamandra U, Anantaram J, Subramanian S, et al. Penicilliosis presenting as fungating skin lesion. J Infect Chemother 2011; 17:700–702.
47. Angus BJ, Schmid ML, Dockrell DH, Grant AD. 10 Travel-related opportunistic infections. HIV Med 2011; 12 (Suppl. 2):88–101.
48. Chaiwarith R, Fakthongyoo A, Praparattanapan J, et al. Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand. Curr HIV Res 2011; 9:334–338.
49. Ramos-e-Silva M, Vasconcelos C, Carneiro S, Cestari T. Sporotrichosis. Clin Dermatol 2007; 25:181–187.
50. Tang MM, Tang JJ, Gill P, et al. Cutaneous sporotrichosis: a six year review of 19 cases in a tertiary referral center in Malaysia. Int J Dermatol 2013; 51:702–708.
51. Morris Jones R. Sporotrichosis. Clin Exp Dermatol 2002; 27:427–431.
52. Song Y, Yao L, Zhong SX, et al. Infant sporotrichosis in northeast China: a report of 15 cases. Int J Dermatol 2011; 50:522–529.
53. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Disease Society of America. Clin Infect Dis 2007; 45:1255–1265.
54. Gutierrez-Galhardo MC, do Valle ACF, Fraga BLB, et al. Disseminated sporotrichosis as a manifestation of immune reconstitution inflammatory syndrome. Mycoses 2010; 53 (Issue 1):78–80.
55. Feeney KT, Arthur IH, Whittle AJ, et al. Outbreak of sporotrichosis, Western Australia. Emerg Inf Dis 2007; 13:1228–1231.
56. Barros MBL, Schubach AO, Valle ACF, et al. Cat-transmitted sporotrichosis epidemic in Rio de Janiero, Brazil: description of a series of cases. Clin Infect Dis 2004; 38:529–535.
57. Liu X, Zhang Z, Hou B, et al. Rapid identification of Sporothrix schenckii in biopsy tissue by PCR. JEADV 2013; 27:1491–1497.
58. Bonifaz A, Fierro L, Saúl A, Ponce RM. Cutaneous sporotrichosis. Intermittent treatment (pulses) with itraconazole. Eur J Dermatol 2008; 18:61–64.
59. Song Y, Zhong S-X, Yao L, et al. Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. JEADV 2011; 25:302–305.
60. Francesconi G, do Valle ACF, Passos SL, et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia 2011; 171:349–354.
61. Francesconi G, Valle AC, Passos S, et al. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. JEADV 2009; 23:1273–1276.
62. Yamada K, Zaitz C, De Souza Framil VM, Muramatu LH. Cutaneous sporotrichosis treatment with potassium iodide. A 24 year experience in São Paulo state, Brazil. Rev Inst Med Trop 2011; 53:89–93.
63. Jernigan JA, Farr BM. Incubation period and sources of exposure for cutaneous Mycobacterium marinum infection: case report and review of the literature. Clin Infect Dis 2000; 31:439–443.
64. Petrini B. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis 2006; 25:609–613.
65. Bhatty MA, Turner DP, Chamberlain ST. Mycobacterium marinum hand infection: case reports and review of literature. Br J Plast Surg 2000; 53:161–165.
66. Parent LJ, Salam MM, Appelbaum PC, Dosset JH. Disseminated Mycobacterium marinum infection and bacteremia in a child with severe combined immunodeficiency. Clin Infect Dis 1995; 21:1325–1327.
67. Salvana EM, Cooper GW, Salata RA. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infec Dec 2007; 55:484–487.
68. Ang P, Rattana-Apiromyakij N, Goh CL. Retrospective study of Mycobacterium marinum skin infections. Int J Dermatol 2000; 39:343–347.
69. Pandian TK, Deziel PJ, Otley CC, et al. Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis 2008; 10:358–363.
70. van Ingen J. Diagnosis of nontuberculous mycobacterial infections. Semin Respir Crit Care Med 2013; 34:103–109.
71. Ho MH, Ho CK, Chong LY. Atypical mycobacterial cutaneous infections in Hong Kong: 10 year retrospective study. Hong Kong Med J 2006; 12:21–26.
72. Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Expert Opin Pharmacother 2007; 8:2965–2978.
73. Huminer D, Pitlik SD, Block C, et al. Aquarium-borne Mycobacterium marinum skin infection. Report of a case and review of the literature. Arch Dermatol 1986; 122:698–703.
74. Wu TS, Chiu CH, Su LH, et al. Mycobacterium marinum infection in Taiwan. J Microbiol Immunol Infect 2002; 35:42–46.
75. Edelstein H. Mycobacterium marinum skin infection. Arch Intern Med 1994; 154:1359–1364.
76. Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162:1746–1752.
77. Mainousa ME, Smith SA. Efficacy of common disinfectants against Mycobacterium marinum. J Aqua Anim Health 2005; 17:284–288.
78. Tian WW, Wang QQ, Liu WD, et al. Mycobacterium marinum: a potential immunotherapy for Mycobacterium tuberculosis infection. Drug Des Devel Ther 2013; 7:669–680.
Keywords:

melioidosis; Mycobacterium marinum; penicilliosis; south-east Asia; sporotrichosis

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.